| Basics |
Intellia Therapeutics, Inc.
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
|
| IPO Date: |
May 6, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.11B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.12 | 3.20%
|
| Avg Daily Range (30 D): |
$0.48 | 4.23%
|
| Avg Daily Range (90 D): |
$0.57 | 3.82%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.23M |
| Avg Daily Volume (30 D): |
8.55M |
| Avg Daily Volume (90 D): |
6.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
77 |
| Avg Trade Size (Sh.) (30 D): |
113 |
| Avg Trade Size (Sh.) (90 D): |
103 |
| Institutional Trades |
| Total Inst.Trades: |
4,760 |
| Avg Inst. Trade: |
$2.94M |
| Avg Inst. Trade (30 D): |
$2.25M |
| Avg Inst. Trade (90 D): |
$2.49M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.83M |
| Avg Closing Trade (30 D): |
$4.44M |
| Avg Closing Trade (90 D): |
$5.72M |
| Avg Closing Volume: |
154.83K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.92
|
$-.98
|
|
Diluted EPS
|
|
$-.92
|
$-.98
|
|
Revenue
|
$
|
$ 13.78M
|
$ 14.25M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -101.32M
|
$ -101.26M
|
|
Operating Income / Loss
|
$
|
$ -111.48M
|
$ -110M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 37.22M
|
$ -32.66M
|
|
PE Ratio
|
|
|
|
|
|
|
